Atherosclerosis Drug Development in Jeopardy: The Need for Predictive Biomarkers of Treatment Response

See allHide authors and affiliations

Science Translational Medicine  02 Mar 2011:
Vol. 3, Issue 72, pp. 72cm6
DOI: 10.1126/scitranslmed.3002029

eLetters is an online forum for ongoing peer review. Submission of eLetters are open to all. Please read our Terms of Service before submitting your own eLetter.

Compose eLetter

Plain text

  • Plain text
    No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

  • Better models, not better biomarkers

    We need a far better model that explains the cause of atherosclerosis and predicts undesirable outcomes. The biomarkers will be the best predictor variables of the model. It is counterproductive to attempt to improve biomarkers without a good model of atherosclerosis. Statistically, integration (combination) of biomarkers create the misleading perception that they make better predictors. But such empirical data is likely t...

    Show More
    Competing Interests: None declared.

Stay Connected to Science Translational Medicine

Navigate This Article